Total Payments
$3,747
2024 Payments
$427.45
Companies
29
Transactions
259
Medicare Patients
6,212
Medicare Billing
$623,181
Payment Breakdown by Category
Food & Beverage$3,696 (98.6%)
Education$50.80 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,696 | 254 | 98.6% |
| Education | $50.80 | 5 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1,339 | 112 | $0 (2024) |
| Genentech USA, Inc. | $347.67 | 29 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $222.10 | 17 | $0 (2024) |
| United Therapeutics Corporation | $205.50 | 10 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $199.82 | 15 | $0 (2022) |
| Insmed, Inc. | $162.43 | 8 | $0 (2024) |
| GENZYME CORPORATION | $145.31 | 6 | $0 (2024) |
| Penumbra, Inc. | $133.55 | 1 | $0 (2023) |
| Mallinckrodt Enterprises LLC | $116.24 | 7 | $0 (2019) |
| Grifols USA, LLC | $103.23 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $427.45 | 25 | GlaxoSmithKline, LLC. ($235.92) |
| 2023 | $582.61 | 31 | GlaxoSmithKline, LLC. ($166.64) |
| 2022 | $292.54 | 14 | Olympus America Inc. ($87.59) |
| 2021 | $274.18 | 22 | GlaxoSmithKline, LLC. ($136.05) |
| 2020 | $364.19 | 28 | GlaxoSmithKline, LLC. ($139.66) |
| 2019 | $705.12 | 51 | GlaxoSmithKline, LLC. ($211.06) |
| 2018 | $811.92 | 64 | GlaxoSmithKline, LLC. ($265.27) |
| 2017 | $288.80 | 24 | GlaxoSmithKline, LLC. ($107.87) |
All Payment Transactions
259 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.62 | General |
| Category: RESPIRATORY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $3.27 | General |
| Category: RESPIRATORY | ||||||
| 10/17/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 10/16/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: IMMUNOLOGY | ||||||
| 09/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: IMMUNOLOGY | ||||||
| 08/22/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: IMMUNOLOGY | ||||||
| 08/20/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $11.49 | General |
| Category: RESPIRATORY | ||||||
| 08/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: Immunology | ||||||
| 08/01/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 07/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $1.66 | General |
| Category: RESPIRATORY | ||||||
| 06/26/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: RESPIRATORY | ||||||
| 06/20/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 05/14/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: RESPIRATORY | ||||||
| 05/09/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: IMMUNOLOGY | ||||||
| 04/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: Cardio-pulmonary | ||||||
| 04/17/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: IMMUNOLOGY | ||||||
| 04/11/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: Respiratory | ||||||
| 04/03/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $2.33 | General |
| Category: RESPIRATORY | ||||||
| 02/27/2024 | Shionogi Inc | Fetroja (Drug) | Education | In-kind items and services | $13.20 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/15/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 02/08/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: RESPIRATORY | ||||||
| 01/22/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: IMMUNOLOGY | ||||||
| 01/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: RESPIRATORY | ||||||
| 01/09/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $28.76 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,485 | 2,416 | $541,149 | $158,520 |
| 2022 | 17 | 1,393 | 2,117 | $460,315 | $128,569 |
| 2021 | 18 | 1,471 | 2,415 | $498,997 | $151,214 |
| 2020 | 24 | 1,863 | 4,628 | $621,904 | $184,878 |
Total Patients
6,212
Total Services
11,576
Medicare Billing
$623,181
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 231 | 583 | $122,430 | $51,728 | 42.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 243 | 497 | $75,544 | $29,537 | 39.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 190 | 301 | $67,725 | $24,825 | 36.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 87 | 88 | $37,400 | $11,133 | 29.8% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 244 | 387 | $71,595 | $6,930 | 9.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 87 | 102 | $13,260 | $6,063 | 45.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 37 | 40 | $19,400 | $6,000 | 30.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 52 | 52 | $14,300 | $4,583 | 32.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $11,100 | $4,227 | 38.1% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 54 | 62 | $46,500 | $3,753 | 8.1% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 104 | 134 | $36,850 | $3,134 | 8.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 25 | 25 | $5,600 | $1,760 | 31.4% |
| 92950 | Manual attempt to restore blood circulation and breathing | Facility | 2023 | 12 | 12 | $8,700 | $1,661 | 19.1% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 24 | 32 | $4,800 | $1,224 | 25.5% |
| 71271 | Low dose ct scan of chest for lung cancer screening | Office | 2023 | 13 | 13 | $3,250 | $1,081 | 33.2% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 18 | 19 | $2,375 | $610.66 | 25.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 27 | 32 | $320.00 | $268.80 | 84.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 230 | 479 | $100,590 | $36,507 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 173 | 276 | $62,100 | $23,514 | 37.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 234 | 408 | $62,016 | $21,093 | 34.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 80 | 83 | $35,275 | $11,781 | 33.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 100 | 121 | $15,730 | $7,185 | 45.7% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 230 | 377 | $69,745 | $6,739 | 9.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 32 | 35 | $16,975 | $5,457 | 32.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 38 | 39 | $10,725 | $3,712 | 34.6% |
About Dr. Matthew Mabie, MD
Dr. Matthew Mabie, MD is a Pulmonary Disease healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063491280.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Mabie, MD has received a total of $3,747 in payments from pharmaceutical and medical device companies, with $427.45 received in 2024. These payments were reported across 259 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($3,696).
As a Medicare-enrolled provider, Mabie has provided services to 6,212 Medicare beneficiaries, totaling 11,576 services with total Medicare billing of $623,181. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location Memphis, TN
- Active Since 01/16/2006
- Last Updated 06/07/2021
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1063491280
Products in Payments
- TRELEGY ELLIPTA (Drug) $653.92
- NUCALA (Biological) $468.68
- Xolair (Biological) $295.62
- Arikayce (Drug) $162.43
- ACTHAR (Biological) $134.28
- Smart Coil (Device) $133.55
- TYVASO (Drug) $124.44
- DUPIXENT (Biological) $100.78
- ANORO (Drug) $98.32
- Spiration Valve System (Device) $87.59
- OFEV (Drug) $86.18
- ORENITRAM (Drug) $81.06
- SPIRIVA RESPIMAT (Drug) $80.56
- AVYCAZ (Drug) $69.87
- ANORO ELLIPTA (Drug) $67.72
- DUPIXENT (Drug) $64.37
- Prolastin-C (Biological) $57.53
- OPSUMIT MACITENTAN (Drug) $55.02
- ELIQUIS (Drug) $53.34
- Esbriet (Biological) $52.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Memphis
Anthony Mattox, D.o, D.O
Pulmonary Disease — Payments: $21,781
Pulmonary Disease $21,781
Dr. Nathan Wilds, Md, MD
Pulmonary Disease — Payments: $20,941
Pulmonary Disease $20,941
Jeffrey Wright, M.d, M.D
Pulmonary Disease — Payments: $15,147
Pulmonary Disease $15,147
Robert Aguillard, Md, MD
Pulmonary Disease — Payments: $11,075
Pulmonary Disease $11,075
Roy Fox, Md, MD
Pulmonary Disease — Payments: $10,189
Pulmonary Disease $10,189
Dr. Kimberly Marsh, M.d, M.D
Pulmonary Disease — Payments: $9,654
Pulmonary Disease $9,654